EdiGene snags about $67m Series B

Beijing-based EdiGene, Inc., a developer of genome editing technologies, has raised about $67 million in Series B financing. 3H Health Investment led the round with participation from other investors that included Sequoia Capital China, Alwin Capital, Kunlun Capital, IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners.

Source: Press Release